Product Description
Navitoclax is a BCL-XL/BCL-2 inhibitor that is being investigated to treat myelofibrosis. (Sourced from: https://www.abbvie.com/our-science/pipeline/navitoclax.html)
Mechanisms of Action: BCL2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czech Republic, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Netherlands, New Zealand, Poland, Puerto Rico, Russia, Serbia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 12
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Myelofibrosis
Phase 2: Acute Lymphoid Leukemia|Myelodysplastic Syndrome|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Preleukemia
Phase 1: Acute Myeloid Leukemia|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Myeloproliferative Disorders|Oncology Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05455294 |
NCT05455294 | P1 |
Active, not recruiting |
Myelodysplastic Syndrome|Myelofibrosis|Myeloproliferative Disorders|Preleukemia|Acute Myeloid Leukemia |
2025-12-31 |
12% |
2025-01-30 |
Primary Completion Date|Primary Endpoints|Treatments |
NCT00788684 |
M10-166 | P1 |
Completed |
Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Lymphoma, Non-Hodgkin |
2025-02-07 |
2% |
2025-02-21 |
Primary Endpoints |
jRCT2080224824 |
jRCT2080224824 | P1 |
Completed |
Oncology Unspecified |
2024-09-08 |
|||
NCT05054465 |
ITALLI001 | P2 |
Not yet recruiting |
Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2025-08-01 |
2022-08-02 |
Primary Endpoints|Treatments |
|
2023-507274-40-00 |
M19-753 | P1 |
Active, not recruiting |
Myelofibrosis |
2025-06-03 |
2025-05-02 |
Treatments |
|
JapicCTI-194907 |
JapicCTI-194907 | P1 |
Active |
Oncology Unspecified |
2021-07-21 |
|||
NCT04472598 |
TRANSFORM-1 | P3 |
Completed |
Myelofibrosis |
2023-04-13 |
24% |
2025-02-22 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05564650 |
22P.205 | P2 |
Active, not recruiting |
Preleukemia|Myelodysplastic Syndrome |
2026-04-10 |
50% |
2025-02-12 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
2023-507276-53-00 |
M16-109 | P2 |
Completed |
Myelofibrosis |
2025-01-28 |
2025-05-02 |
Treatments |
|
NCT05192889 |
RAVEN | P2 |
Active, not recruiting |
Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2024-06-13 |
2% |
2024-11-27 |
Primary Endpoints |
NCT04468984 |
TRANSFORM-2 | P3 |
Active, not recruiting |
Myelofibrosis |
2025-01-29 |
72% |
2025-04-26 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Treatments |
NCT04041050 |
M19-753 | P1 |
Active, not recruiting |
Myeloproliferative Disorders |
2026-12-31 |
12% |
2025-02-15 |
Primary Endpoints |